Selected research
Industry Research
Systemic Aspergillosis and Systemic Candidasis Industry Research Report 2026
Market perspective
The global Systemic Aspergillosis and Systemic Candidasis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Systemic Aspergillosis and Systemic Candidasis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Systemic Aspergillosis and Systemic Candidasis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Systemic Aspergillosis and Systemic Candidasis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Systemic Aspergillosis and Systemic Candidasis include Abbott, Novartis AG, Merck & Co., Inc, Pfizer, Inc, GlaxoSmithKline plc, Bayer AG, Sanofi-Aventis, Enzon Pharmaceuticals, Inc and Astellas Pharma, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Systemic Aspergillosis and Systemic Candidasis market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Systemic Aspergillosis and Systemic Candidasis Market by Company
Abbott
Novartis AG
Merck & Co., Inc
Pfizer, Inc
GlaxoSmithKline plc
Bayer AG
Sanofi-Aventis
Enzon Pharmaceuticals, Inc
Astellas Pharma, Inc
Systemic Aspergillosis and Systemic Candidasis Segment by Type
Liposomal Amphotericin B
Systemic Oral Azoles
Topical Antifungal Agents
Voriconazole
Other
Systemic Aspergillosis and Systemic Candidasis Segment by Application
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
CPA
ABPA
Other
Systemic Aspergillosis and Systemic Candidasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Aspergillosis and Systemic Candidasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Systemic Aspergillosis and Systemic Candidasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Aspergillosis and Systemic Candidasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Systemic Aspergillosis and Systemic Candidasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Systemic Aspergillosis and Systemic Candidasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Systemic Aspergillosis and Systemic Candidasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomal Amphotericin B
- Systemic Oral Azoles
- Topical Antifungal Agents
- Voriconazole
- Other
Applications
- Gastrointestinal Candidiasis
- Genitourinary Tract Candidiasis
- CPA
- ABPA
- Other
Companies covered
- Abbott
- Novartis AG
- Merck & Co., Inc
- Pfizer, Inc
- GlaxoSmithKline plc
- Bayer AG
- Sanofi-Aventis
- Enzon Pharmaceuticals, Inc
- Astellas Pharma, Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Systemic Aspergillosis and Systemic Candidasis Market Size (2021-2032)
- 2.2.2 Global Systemic Aspergillosis and Systemic Candidasis Sales (2021-2032)
- 2.2.3 Global Systemic Aspergillosis and Systemic Candidasis Market Average Price (2021-2032)
- 2.3 Systemic Aspergillosis and Systemic Candidasis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Liposomal Amphotericin B
- 2.3.3 Systemic Oral Azoles
- 2.3.4 Topical Antifungal Agents
- 2.3.5 Voriconazole
- 2.3.6 Other
- 2.4 Systemic Aspergillosis and Systemic Candidasis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gastrointestinal Candidiasis
- 2.4.3 Genitourinary Tract Candidiasis
- 2.4.4 CPA
- 2.4.5 ABPA
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Systemic Aspergillosis and Systemic Candidasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Systemic Aspergillosis and Systemic Candidasis Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue of Manufacturers (2021-2026)
- 3.4 Global Systemic Aspergillosis and Systemic Candidasis Average Price by Manufacturers (2021-2026)
- 3.5 Global Systemic Aspergillosis and Systemic Candidasis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Systemic Aspergillosis and Systemic Candidasis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Systemic Aspergillosis and Systemic Candidasis, Product Type & Application
- 3.8 Global Manufacturers of Systemic Aspergillosis and Systemic Candidasis, Established Date
- 3.9 Global Systemic Aspergillosis and Systemic Candidasis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 Merck & Co., Inc
- 4.3.1 Merck & Co., Inc Company Information
- 4.3.2 Merck & Co., Inc Business Overview
- 4.3.3 Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.3.5 Merck & Co., Inc Recent Developments
- 4.4 Pfizer, Inc
- 4.4.1 Pfizer, Inc Company Information
- 4.4.2 Pfizer, Inc Business Overview
- 4.4.3 Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.4.5 Pfizer, Inc Recent Developments
- 4.5 GlaxoSmithKline plc
- 4.5.1 GlaxoSmithKline plc Company Information
- 4.5.2 GlaxoSmithKline plc Business Overview
- 4.5.3 GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.5.5 GlaxoSmithKline plc Recent Developments
- 4.6 Bayer AG
- 4.6.1 Bayer AG Company Information
- 4.6.2 Bayer AG Business Overview
- 4.6.3 Bayer AG Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer AG Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.6.5 Bayer AG Recent Developments
- 4.7 Sanofi-Aventis
- 4.7.1 Sanofi-Aventis Company Information
- 4.7.2 Sanofi-Aventis Business Overview
- 4.7.3 Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.7.5 Sanofi-Aventis Recent Developments
- 4.8 Enzon Pharmaceuticals, Inc
- 4.8.1 Enzon Pharmaceuticals, Inc Company Information
- 4.8.2 Enzon Pharmaceuticals, Inc Business Overview
- 4.8.3 Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.8.5 Enzon Pharmaceuticals, Inc Recent Developments
- 4.9 Astellas Pharma, Inc
- 4.9.1 Astellas Pharma, Inc Company Information
- 4.9.2 Astellas Pharma, Inc Business Overview
- 4.9.3 Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
- 4.9.5 Astellas Pharma, Inc Recent Developments
5 Global Systemic Aspergillosis and Systemic Candidasis Market Scenario by Region
- 5.1 Global Systemic Aspergillosis and Systemic Candidasis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region: 2021-2032
- 5.2.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region: 2021-2026
- 5.2.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region: 2027-2032
- 5.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region: 2021-2032
- 5.3.1 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region: 2021-2026
- 5.3.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region: 2027-2032
- 5.4 North America Systemic Aspergillosis and Systemic Candidasis Market Facts & Figures by Country
- 5.4.1 North America Systemic Aspergillosis and Systemic Candidasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
- 5.4.3 North America Systemic Aspergillosis and Systemic Candidasis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Systemic Aspergillosis and Systemic Candidasis Market Facts & Figures by Country
- 5.5.1 Europe Systemic Aspergillosis and Systemic Candidasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
- 5.5.3 Europe Systemic Aspergillosis and Systemic Candidasis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Systemic Aspergillosis and Systemic Candidasis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Systemic Aspergillosis and Systemic Candidasis Market Facts & Figures by Country
- 5.7.1 South America Systemic Aspergillosis and Systemic Candidasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
- 5.7.3 South America Systemic Aspergillosis and Systemic Candidasis Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021-2032)
- 6.1.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Type (2021-2032)
- 6.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type (2021-2032)
- 6.2.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Type (2021-2032)
- 6.3 Global Systemic Aspergillosis and Systemic Candidasis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021-2032)
- 7.1.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Application (2021-2032)
- 7.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application (2021-2032)
- 7.2.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Application (2021-2032)
- 7.3 Global Systemic Aspergillosis and Systemic Candidasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Systemic Aspergillosis and Systemic Candidasis Value Chain Analysis
- 8.1.1 Systemic Aspergillosis and Systemic Candidasis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Systemic Aspergillosis and Systemic Candidasis Production Mode & Process
- 8.2 Systemic Aspergillosis and Systemic Candidasis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Systemic Aspergillosis and Systemic Candidasis Distributors
- 8.2.3 Systemic Aspergillosis and Systemic Candidasis Customers
9 Global Systemic Aspergillosis and Systemic Candidasis Analyzing Market Dynamics
- 9.1 Systemic Aspergillosis and Systemic Candidasis Industry Trends
- 9.2 Systemic Aspergillosis and Systemic Candidasis Industry Drivers
- 9.3 Systemic Aspergillosis and Systemic Candidasis Industry Opportunities and Challenges
- 9.4 Systemic Aspergillosis and Systemic Candidasis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst